Earnings call transcript: Crizac Q2 2026 revenue drops 37% as stock slips

Crizac’s Q2 FY27 operating income fell 36.7% year on year to INR 1,027 million, operating EBITDA dropped 44% to INR 330 million, and PAT declined 23.7% to INR 369 million, as West Asia-related travel disruption, currency volatility and student deferrals affected its U.K.-concentrated education business. Applications fell only 3%, which management said supports its view that enrollments were deferred rather than lost; it forecast Q3 FY27 revenue growth of 10%–12% year on year and FY27 revenue and profit in line with FY26. The company reported net cash of INR 5,958 million and declared an interim dividend of INR 4 per share, while shares were down 1.41% at $136.61, near their 52-week low.

Analysis

The key underwriting question is conversion, not whether applications held up. Revenue recognition follows course start and university confirmation, so the claimed deferral recovery shifts risk into Q3/Q4: visas, deposits and applications are not equivalent to enrolled, commission-generating students. Management’s 10–12% Q3 growth outlook is a near-term test, but full-year revenue and profit merely matching FY26 implies limited room for further slippage. The 136% H1 operating-cash-flow conversion is partly working-capital timing and should not be capitalized as a steady-state earnings signal.

The most consequential second-order exposure is concentration: UK policy or travel friction can hit both student conversion and the economics of university recruitment, while three universities account for a substantial revenue share. Diversification applications are not yet revenue; the gap is execution risk, not just upside optionality. A UK graduate-route proposal is a potential sentiment catalyst, but eligibility rules remain undefined and should not be treated as policy resolution. Larger, compliance-capable platforms may gain university share if recruitment partners consolidate; conversely, universities’ own AI tools could pressure intermediary economics over time, even if human counseling persists.

Trade stance: no dip-buy on oversold technicals alone. Consider a staged long only after Q3 enrollment-linked revenue confirms the bridge and full-year guidance holds; otherwise the stock risks a credibility discount despite net cash. No clean pair is supported by the supplied facts. Falsifiers: Q3 growth below guidance, evidence deferrals are cancellations, FY27 guidance cut, or continued UK concentration without conversion of non-UK applications. Reassess after Q3 results; structural diversification is a multi-year—not near-term—catalyst.

Key Decisions for Investors

• Keep exposure tactical rather than treating the share-price weakness as a valuation signal; the article provides no independently verifiable valuation or consensus data.
• Set a Q3 results trigger: require revenue growth within management’s 10–12% year-on-year range and evidence of enrollment/visa conversion before adding risk.
• Track quarterly applications-to-enrollment conversion, revenue per enrollment, and UK versus non-UK revenue; do not count non-UK application growth as diversification until it appears in recognized revenue.
• Discount H1 cash conversion and monitor whether investment, acquisition spending, and dividends preserve the net-cash position; avoid assigning value to unannounced M&A or AI monetization.